JP7750525B2 - 新規なｔｌｒ９アゴニスト - Google Patents

新規なｔｌｒ９アゴニスト

Info

Publication number
JP7750525B2
JP7750525B2 JP2022534852A JP2022534852A JP7750525B2 JP 7750525 B2 JP7750525 B2 JP 7750525B2 JP 2022534852 A JP2022534852 A JP 2022534852A JP 2022534852 A JP2022534852 A JP 2022534852A JP 7750525 B2 JP7750525 B2 JP 7750525B2
Authority
JP
Japan
Prior art keywords
seq
cells
oligonucleotide
odn
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022534852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510491A (ja
JP2023510491A5 (OSRAM
Inventor
永二 江指
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Publication of JP2023510491A publication Critical patent/JP2023510491A/ja
Publication of JP2023510491A5 publication Critical patent/JP2023510491A5/ja
Application granted granted Critical
Publication of JP7750525B2 publication Critical patent/JP7750525B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022534852A 2020-01-10 2021-01-08 新規なｔｌｒ９アゴニスト Active JP7750525B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020002715 2020-01-10
JP2020002715 2020-01-10
PCT/JP2021/000543 WO2021141121A1 (en) 2020-01-10 2021-01-08 Novel tlr9 agonists

Publications (3)

Publication Number Publication Date
JP2023510491A JP2023510491A (ja) 2023-03-14
JP2023510491A5 JP2023510491A5 (OSRAM) 2023-06-19
JP7750525B2 true JP7750525B2 (ja) 2025-10-07

Family

ID=76787976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534852A Active JP7750525B2 (ja) 2020-01-10 2021-01-08 新規なｔｌｒ９アゴニスト

Country Status (11)

Country Link
US (1) US20230323368A1 (OSRAM)
EP (1) EP4087931B1 (OSRAM)
JP (1) JP7750525B2 (OSRAM)
KR (1) KR20220125218A (OSRAM)
CN (1) CN114981436A (OSRAM)
AU (1) AU2021206355A1 (OSRAM)
BR (1) BR112022007935A2 (OSRAM)
CA (1) CA3161956A1 (OSRAM)
IL (1) IL294621A (OSRAM)
MX (1) MX2022005633A (OSRAM)
WO (1) WO2021141121A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313315A4 (en) * 2021-04-01 2025-02-19 TriSalus Life Sciences, Inc. CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS
CN117568339A (zh) * 2023-01-19 2024-02-20 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508693A (ja) 2002-08-19 2006-03-16 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性核酸
US20110136897A1 (en) 2008-08-14 2011-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
WO2014201516A2 (en) 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
WO2017181128A1 (en) 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
WO2018087699A2 (en) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Methods and compositions for adaptive immune modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010001785A (es) * 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
AU2010229835B2 (en) * 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508693A (ja) 2002-08-19 2006-03-16 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性核酸
US20110136897A1 (en) 2008-08-14 2011-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
WO2014201516A2 (en) 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
WO2017181128A1 (en) 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
WO2018087699A2 (en) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Methods and compositions for adaptive immune modulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Advanced Drug Delivery Reviews，2009年，Vol.61，p.195-204，doi:10.1016/j.addr.2008.12.008
Journal of Bacteriology，2006年，Vol.188, No.22，p.7893-7904，doi:10.1128/JB.00711-06
Molecular Ecology Resources，2009年，Vol.9, No.6，p.1554-1556，doi:10.111/j.1755-0998.2009.02736.x

Also Published As

Publication number Publication date
IL294621A (en) 2022-09-01
US20230323368A1 (en) 2023-10-12
KR20220125218A (ko) 2022-09-14
JP2023510491A (ja) 2023-03-14
CA3161956A1 (en) 2021-07-15
BR112022007935A2 (pt) 2022-07-12
AU2021206355A1 (en) 2022-07-07
MX2022005633A (es) 2022-06-14
EP4087931B1 (en) 2024-12-25
CN114981436A (zh) 2022-08-30
EP4087931A1 (en) 2022-11-16
WO2021141121A1 (en) 2021-07-15
EP4087931A4 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
JP7556848B2 (ja) ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物
JP7457642B2 (ja) タンパク質抗原およびその使用
JP2024105596A (ja) ネオ抗原およびその使用方法
JP6885867B2 (ja) 組合せ腫瘍免疫療法
KR102148866B1 (ko) 암 치료를 위한 t 세포의 활성화 방법
JP7366057B2 (ja) 合成ｒｉｇ－ｉ様受容体アゴニスト
JP2021512090A (ja) 免疫細胞に薬剤を送達するための組成物及び方法
US20150010613A1 (en) Compositions and methods for cancer immunotherapy
KR20190039969A (ko) 암 치료법을 위한 rna
CN110770345A (zh) 免疫调节多核苷酸、抗体缀合物及其使用方法
CN110229813B (zh) 具有疫苗佐剂作用和肿瘤治疗作用的寡核苷酸
KR20140014077A (ko) 교모세포종의 치료를 위한 치료 조성물
JP2017509652A (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
EP4087931B1 (en) Novel tlr9 agonists
CN106893724B (zh) 具有抗原增效作用和肿瘤治疗作用的寡核苷酸
RU2846775C1 (ru) Новые агонисты tlr9
Jeon Role of toll-like receptor agonists as cancer vaccine adjuvants
CA3252966A1 (en) Individualized Cancer Epitopes and Their Methods of Use
Turk Regulatory T cells and cancer
CN114761558A (zh) 新型核糖核酸和基于其的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250917

R150 Certificate of patent or registration of utility model

Ref document number: 7750525

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150